Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Ilmarinen Mutual Pension Insurance Co

Ilmarinen Mutual Pension Insurance Co lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 59.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 174,000 shares of the biopharmaceutical company’s stock after purchasing an additional 65,000 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Gilead Sciences were worth $16,072,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. HHM Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences in the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust acquired a new position in Gilead Sciences during the 4th quarter valued at approximately $31,000. Finally, Stephens Consulting LLC increased its stake in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Down 4.6 %

Shares of NASDAQ:GILD opened at $107.25 on Friday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business has a fifty day moving average of $107.30 and a two-hundred day moving average of $95.80. The stock has a market cap of $133.54 billion, a P/E ratio of 289.86, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.95%. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GILD. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. BMO Capital Markets increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Finally, Piper Sandler increased their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $105.12.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 302,785 shares of company stock worth $30,503,250 over the last quarter. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.